Intra-Cellular Therapies Inc (ITCI) Expected to Post Earnings of -$0.86 Per Share

Analysts expect Intra-Cellular Therapies Inc (NASDAQ:ITCI) to post ($0.86) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Intra-Cellular Therapies’ earnings, with the lowest EPS estimate coming in at ($1.01) and the highest estimate coming in at ($0.77). Intra-Cellular Therapies reported earnings of ($0.68) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 26.5%. The firm is expected to report its next quarterly earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Intra-Cellular Therapies will report full-year earnings of ($3.72) per share for the current year, with EPS estimates ranging from ($4.15) to ($3.24). For the next financial year, analysts expect that the company will report earnings of ($2.95) per share, with EPS estimates ranging from ($3.90) to ($2.45). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Intra-Cellular Therapies.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.27.

A number of research analysts have commented on ITCI shares. ValuEngine cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. BidaskClub cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $26.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $27.00.

ITCI stock opened at $12.44 on Tuesday. Intra-Cellular Therapies has a 12-month low of $10.21 and a 12-month high of $23.64. The company has a quick ratio of 9.59, a current ratio of 9.59 and a debt-to-equity ratio of 0.07. The stock has a market cap of $681.24 million, a price-to-earnings ratio of -4.38 and a beta of 1.39.

In other news, Director Christopher D. Alafi acquired 100,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were purchased at an average price of $12.56 per share, for a total transaction of $1,256,000.00. Following the completion of the purchase, the director now directly owns 750,106 shares of the company’s stock, valued at approximately $9,421,331.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 17.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ITCI. MetLife Investment Advisors LLC raised its stake in Intra-Cellular Therapies by 55.8% during the third quarter. MetLife Investment Advisors LLC now owns 30,540 shares of the biopharmaceutical company’s stock valued at $663,000 after buying an additional 10,934 shares in the last quarter. Vanguard Group Inc. raised its stake in Intra-Cellular Therapies by 1.8% during the third quarter. Vanguard Group Inc. now owns 3,943,792 shares of the biopharmaceutical company’s stock valued at $85,580,000 after buying an additional 69,950 shares in the last quarter. Vanguard Group Inc raised its stake in Intra-Cellular Therapies by 1.8% during the third quarter. Vanguard Group Inc now owns 3,943,792 shares of the biopharmaceutical company’s stock valued at $85,580,000 after buying an additional 69,950 shares in the last quarter. First Midwest Bank Trust Division grew its holdings in shares of Intra-Cellular Therapies by 60.0% during the fourth quarter. First Midwest Bank Trust Division now owns 327,226 shares of the biopharmaceutical company’s stock valued at $3,727,000 after purchasing an additional 122,756 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Intra-Cellular Therapies by 43.6% during the fourth quarter. Rhumbline Advisers now owns 60,872 shares of the biopharmaceutical company’s stock valued at $693,000 after purchasing an additional 18,481 shares during the last quarter. Hedge funds and other institutional investors own 69.34% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Featured Article: What are the benefits of investing in REITs?

Get a free copy of the Zacks research report on Intra-Cellular Therapies (ITCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.